Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 09
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Ovid Therapeutics Inc
OVID
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.34
-0.02
-0.85%
Últ. Act.: Oct 8, 6:31 PM
$2.33
-0.03
-1.27%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Ovid Therapeutics Financials
Ovid Therapeutics (OVID) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Benzinga Newsdesk
PRO
Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share
Benzinga Newsdesk
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics shares climb after positive epilepsy data, new trial launch, and $60 million funding boost extending runway into 2028.
Vandana Singh
Earnings Scheduled For March 18, 2026
Benzinga Insights
PRO
Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 152.63 percent. This is a 146.15 percent increase over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Ovid Therapeutics Q3 EPS $(0.17) Misses $(0.15) Estimate, Sales $132.000K Beat $131.429K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 15.65 percent. This is a 15 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
